PerkinElmer Enters In Vivo Molecular-Imaging Market
Discussing why PerkinElmer invested in this technology, Mr. Eglen told IBO: “We believe that in vivo molecular imaging has the ability to provide quantifiable readouts, reflecting the nature of the disease complexity, which are additional to the data one can obtain using cellular models. Furthermore, it can be used in combination with other imaging technologies to provide very detailed information for the researcher than currently available today.”
Waltham, MA 8/3/10—PerkinElmer has acquired VisEn Medical, an in vivo molecular-imaging technology company, for an undisclosed amount. VisEn’s Fluorescence Molecular Tomographic Imaging Systems and reagents provide quantitative molecular-imaging data for identifying and characterizing disease biomarkers and therapeutic efficacy in cells and animal models. “This acquisition broadens our product portfolio along the drug discovery pipeline, from basic disease-based research to preclinical drug discovery applications, through the addition of proprietary chemistries in the emerging and fast-growing space of translational biomarker reagents,” commented Richard Eglen, president, Bio-discovery, at PerkinElmer.